Aurinia Q4 revenue up 29% to $77.1M, EPS $1.53; guides 2026 LUPKYNIS sales $305M-$315M

Aurinia Pharmaceuticals Inc.

2025-FY EPS reported $2.07 vs consensus $0.22 ▲ beat (+836.7%)

LUPKYNIS net product sales for FY 2025: $271.3M, up 25% YoY; Q4 $74.2M, up 29%.
Net income for FY 2025: $287.2M ($2.07 diluted EPS) vs $5.8M ($0.04) in 2024; includes $173.0M tax benefit.
Cash, equivalents, restricted cash & investments: $398.0M at Dec 31, 2025; generated $135.7M from operations.
2026 guidance: total revenue $315M-$325M; LUPKYNIS net sales $305M-$315M (12-16% growth).
Initiated clinical study of aritinercept (BAFF/APRIL inhibitor); plan another autoimmune study in H1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.